Abbott Laboratories Inc.

Abbott Laboratories Inc., Abbott Vascular Inc. Division supplies cardiovascular medical devices, surgical implants, and related diagnostic equipment to federal healthcare agencies as a 100% prime contractor competing under full and open competition with no set-aside certifications. The division is a wholly owned business unit of Abbott Laboratories, headquartered in Abbott Park, Illinois, with primary operational facilities in Santa Clara, California.

Abbott Vascular's federal footprint centers on two customer bases that diverge significantly in concentration and dollar value. The Department of Veterans Affairs dominates by award count—the top five VISN networks (Veterans Integrated Service Network 8, 2, 15, 7, and 19) account for 29% of recent awards with $58.8 million combined potential value—but the Defense Logistics Agency Medical Supply Chain represents the largest single concentration by dollar value, anchoring 21% of Abbott Vascular's total federal portfolio at $242.9 million combined potential value across 545 awards. The Department of the Army Medical Command ranks third by dollars ($41.8 million across 161 awards). Across 33 distinct federal agencies, Abbott Vascular has maintained a high-velocity delivery model: 306 awards in 2025 and 201 through September 2026 year-to-date, a sustained trajectory from 171 awards in 2022.

Abbott Vascular's product and service capability spans stents, pacemakers (including the AVEIR leadless system), transcatheter heart valves (MitraClip, Epic Plus Mitral, Regent Aortic), implantable cardiac monitors, left ventricular assist devices (HeartMate series, CentriMag), electrophysiology mapping and diagnostic systems (EnSite X, Optis), and maintenance and repair services for installed equipment. Representative recent federal work includes a $420,000 indefinite delivery purchase order from VISN 19 for EnSite support through September 2029; a $360,000 firm fixed-price maintenance contract with the Defense Health Agency for electrophysiology equipment service at Naval Medical Center San Diego through May 2029; a $150,150 purchase order from VISN 4 for cardiac stents (ratification of unauthorized commitment) through September 2026; and numerous Defense Logistics Agency delivery orders ranging from $1,400 to $66,000 for discrete cardiovascular implants and components issued weekly against its $117.1 million comprehensive cardiovascular procedural packages IDC.

Abbott Vascular holds four single-award indefinite delivery contracts (IDCs) with Veterans Integrated Service Networks: a $1,132,650 transcatheter prosthetic surgical heart valve consignment contract with VISN 19 through November 2029; a $500,000 mitral valve consignment contract with VISN 12 through July 2030; a $144,000 left ventricular assist device service plan with VISN 16 through July 2030; and a $2 ceiling consignment heart valve contract with VISN 17 through September 2029 (the minimal ceiling reflects a consignment model where dollars flow on task orders as clinical demand arises). At the Defense Logistics Agency, Abbott Vascular operates under an indefinite delivery contract (VA797N12D0004) that has generated 4,046 task orders worth $21.4 million combined potential value and serves as the primary vehicle for routine cardiovascular device procurements across federal medical supply chains.

Abbott Vascular operates a 100% prime contractor posture across its federal portfolio and does not function as a routine subcontractor—the source records only 15 sub-awards (0% of total), all delivered to Cardinal Health 200, LLC as the prime on Defense Logistics Agency medical supply orders. Across SCI-reportable service contracts, the division reported $68 thousand in invoiced revenue (FY2024–FY2025), with median government-paid hourly rates running approximately $802/hr for maintenance and technical support labor, reflecting specialist technician and equipment support pricing. The relatively low SCI volume reflects Abbott Vascular's business model: the overwhelming majority of federal revenue derives from product sales (surgical implants, devices, diagnostic equipment) rather than labor services, which fall outside SCI's scope.

Activity remains robust. Within the next twenty-four months, 25 awards with combined potential value of $4.9 million reach ultimate completion and face recompete. Abbott Vascular's federal contracting is concentrated in surgical and medical instrument manufacturing (NAICS 339113) and surgical appliance and supplies manufacturing (NAICS 339115), with the Medical and Surgical Instruments, Equipment, and Supplies PSC accounting for 10,437 of its 11,466 total awards. The division competes across full and open mechanisms with established OEM relationships (sole-source justifications citing Abbott as the only authorized manufacturer for specialized cardiac devices such as the OPTIS Integrated Next System and EnSite X EP Mapping System) that anchor long-term consignment and service agreements with regional VA networks, positioning Abbott Vascular as a critical infrastructure supplier to federal healthcare systems across the Department of Veterans Affairs and Department of Defense.